$ALNY · ALNYLAM PHARMACEUTICALS, INC. SEC Filings
Position Tracker tracks 3 SEC EDGAR filings for ALNYLAM PHARMACEUTICALS, INC. ($ALNY) from October 29, 2026 through November 5, 2026, including 0 Form 10-K annual reports, 1 Form 10-Q quarterly earnings reports, 2 Form 8-K current event disclosures, and 0 Form 4 insider equity transactions. Select any filing below to read the full AI summary, key financial takeaways, and original SEC.gov document.
$ALNY 8-K — ALNYLAM PHARMACEUTICALS, INC.
A $1.0 billion buyback signals capital-return confidence, though the concurrent CCO departure adds a leadership-transition watch item.
$ALNY 8-K — ALNYLAM PHARMACEUTICALS, INC.
The 6% extended-hours selloff reveals the market is looking past the GAAP headline — the real story is declining operating income and an 80% collaboration revenue drop, even as…
$ALNY 10-Q — ALNYLAM PHARMACEUTICALS, INC.
The $1.87B tax benefit signals Alnylam's transition to sustained profitability expectations, while AMVUTTRA's 65% growth confirms blockbuster trajectory in the ATTR cardiomyopat…